16. Heller JE, Shadick NA. Outcomes in rheumatoid arthritis: incorporating the patient perspective. Curr Opin Rheumatol 2007;19:101–5. 17. Schoels M, Aletaha D, Smolen JS, et al. Follow-up standards and treatment targets in rheumatoid arthritis (RA): results of a questionnaire at the EULAR 2008. Ann Rheum Dis 2010;69;575–8. 18. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806. 19. Smolen JS, Breedveld FC, Schiff MH, et al. A simpliﬁed disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57. 20. Bray K, Turpin RS, Jungkind K, et al. Deﬁning success in diabetes disease management: digging deeper in the data. Dis Manag 2008;11:119–28. 21. Moses RG. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clin Ther 2008;30:552–4. 22. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525–33. 23. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009;3:CD004349. 24. Ogihara T, Nakao K, Fukui T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res 2008;31:1595–601. 25. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123–31. 26. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9. 27. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Extended report Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9. 28. Fransen J, Bernelot Moens H, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised control trial. Ann Rheum Dis 2005;64:1294–8. 29. Symmons D, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost- effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9:iii–iv, ix–x, 1–78. 30. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensiﬁed COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574–7. 31. Edmonds J, Lassere M, Sharp JT, et al. Objectives study in RA (OSRA): a RCT deﬁning the best clinical target for disease activity control in RA. Ann Rheum Dis 2007;66(Suppl II):325. 32. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inﬂammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157–63. 33. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22–9. 34. Aletaha D, Strand V, Smolen JS, et al. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238–43. 35. Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum 2008;58:2622–31. 36. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47:59–64. 37. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efﬁcacy and feasibility. Ann Rheum Dis 2007;66 (Suppl 3):iii56–60. Ann Rheum Dis 2010;69:638–643. doi:10.1136/ard.2009.123976 03_ar123976.indd 643 643 3/10/2010 11:52:44 AM